Literature DB >> 33542911

Systemic Overexpression of GDF5 in Adipocytes but Not Hepatocytes Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver in Mice.

Yan Yang1, Wenting Zhang1, Xiaohui Wu2, Jing Wu1, Chengjun Sun1, Feihong Luo1, Zhou Pei1.   

Abstract

Objective: Our recent study demonstrated that growth differentiation factor 5 (GDF5) could promote white adipose tissue thermogenesis and alleviate high-fat diet- (HFD-) induced obesity in fatty acid-binding protein 4- (Fabp4-) GDF5 transgenic mice (TG). Here, we further investigated the effects of systemic overexpression of the GDF5 gene in adipocytes HFD-induced nonalcoholic fatty liver disease (NAFLD).
Methods: Fabp4-GDF5 TG mice were administered an HFD feeding. NAFLD-related indicators associated with lipid metabolism and inflammation were measured. A GDF5 lentiviral vector was constructed, and the LO2 NAFLD cell model was induced by FFA solution (oleic acid and palmitic acid). The alterations in liver function, liver lipid metabolism, and related inflammatory indicators were analyzed.
Results: The liver weight was significantly reduced in the TG group, which was in accordance with the significantly downregulated expression of TNFα, MCP1, Aim2, and SREBP-1c and significantly upregulated expression of CPT-1α and ACOX2 in TG mouse livers. Compared to that of cells in the FAA-free control group, LO2 cells with in situ overexpression of GDF5 developed lipid droplets after FFA treatment; the levels of triglycerides, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were significantly increased in both the GDF5 lentivirus and control lentivirus groups compared with those of the FAA-free group. Additionally, the levels of FAS, SREBP-1, CPT-1α, and inflammation-associated genes, such as ASC and NLRC4, were unaltered despite GDF5 treatment.
Conclusion: Systemic overexpression of GDF5 in adipose tissue in vivo significantly reduced HFD-induced NAFLD liver damage in mice. The overexpression of GDF5 in hepatocytes failed to improve lipid accumulation and inflammation-related reactions induced by mixed fatty acids, suggesting that the protective effect of GDF5 in NAFLD was mainly due to the reduction in adipose tissue and improvements in metabolism. Hence, our study suggests that the management of NAFLD should be targeted to reduce the overall amount of body fat and improve metabolic status before the progression to nonalcoholic steatohepatitis occurs.
Copyright © 2021 Yan Yang et al.

Entities:  

Year:  2021        PMID: 33542911      PMCID: PMC7843185          DOI: 10.1155/2021/8894685

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  23 in total

1.  GDF5 Promotes White Adipose Tissue Thermogenesis via p38 MAPK Signaling Pathway.

Authors:  Wenting Zhang; Xiaohui Wu; Zhou Pei; Wieland Kiess; Yan Yang; Yong Xu; Zhuo Chang; Jing Wu; Chengjun Sun; Feihong Luo
Journal:  DNA Cell Biol       Date:  2019-09-25       Impact factor: 3.311

2.  Non-Alcoholic Fatty Liver Disease and Disease Mongering.

Authors:  Alain Braillon
Journal:  Am J Med       Date:  2019-01-11       Impact factor: 4.965

Review 3.  Non-alcoholic fatty liver disease - A global public health perspective.

Authors:  Zobair M Younossi
Journal:  J Hepatol       Date:  2018-11-09       Impact factor: 25.083

4.  Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease.

Authors:  Naoshi Nishida; Norihisa Yada; Satoru Hagiwara; Toshiharu Sakurai; Masayuki Kitano; Masatoshi Kudo
Journal:  J Gastroenterol Hepatol       Date:  2016-09       Impact factor: 4.029

Review 5.  Treatment of NAFLD with diet, physical activity and exercise.

Authors:  Manuel Romero-Gómez; Shira Zelber-Sagi; Michael Trenell
Journal:  J Hepatol       Date:  2017-05-23       Impact factor: 25.083

Review 6.  Nonalcoholic fatty liver disease: from steatosis to cirrhosis.

Authors:  Geoffrey C Farrell; Claire Z Larter
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

7.  Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies.

Authors:  A Katrina Loomis; Shaum Kabadi; David Preiss; Craig Hyde; Vinicius Bonato; Matthew St Louis; Jigar Desai; Jason M R Gill; Paul Welsh; Dawn Waterworth; Naveed Sattar
Journal:  J Clin Endocrinol Metab       Date:  2015-12-16       Impact factor: 5.958

8.  Dynamic profile and adipogenic role of growth differentiation factor 5 (GDF5) in the differentiation of 3T3-L1 preadipocytes.

Authors:  Zhou Pei; Yi Yang; Wieland Kiess; Chengjun Sun; Feihong Luo
Journal:  Arch Biochem Biophys       Date:  2014-07-28       Impact factor: 4.013

9.  Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.

Authors:  Jie Hu; Wei Hong; Kan-Nan Yao; Xiao-Hong Zhu; Zhi-Yun Chen; Lei Ye
Journal:  World J Gastroenterol       Date:  2019-03-28       Impact factor: 5.742

10.  Inhibition of ghrelin o-acyltransferase attenuated lipotoxicity by inducing autophagy via AMPK-mTOR pathway.

Authors:  Shaoren Zhang; Yuqing Mao; Xiaoming Fan
Journal:  Drug Des Devel Ther       Date:  2018-04-18       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.